Version history

1 version on record. Newest first; the live version sits at the top with a live indicator.

  1. Live
    4/26/2026, 8:01:36 AM
    Content snapshot 
    {
  "session_id": "sess_SDA-2026-04-26-trem2-showcase",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "action": "argument",
  "content": "The INVOKE-2 trial (AL002, TREM2 agonist) failed to meet primary endpoints in 2024. This raises questions about mechanism appropriateness, off-target effects from systemic activation, and whether amyloid clearance alone justifies benefit at late stages. TREM2 has dual roles — pro-inflammatory via SYK and potentially protective via metabolic reprogramming — making timing and context critical.",
  "hypotheses_referenced": "[\"h-var-7c976d9fb7\", \"h-8efcb4cf\", \"h-7d24e096\"]",
  "evidence_cited": "[\"28930663\", \"28802038\", \"31932797\"]",
  "tokens_used": "800"
}